BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:GIA632 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of GIA632\, from ClinicalTrials.gov estimate
 s.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07220577-1372@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20270517
DTEND;VALUE=DATE:20270518
SUMMARY:GIA632: Phase 2 readout est. (NCT07220577)
DESCRIPTION:GIA632\, phase 2\, Atopic Dermatitis.\nStudy: Phase 2a Study to
  Assess the Efficacy\,Safety and Tolerability of GIA632 in Adult Participa
 nts With Moderate to Severe Atopic Dermatitis\nEstimated primary completio
 n: 17 May 2027. This is a ClinicalTrials.gov estimate\, not a confirmed re
 adout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/gia63
 2#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07
 220577
URL:https://assetmemo.bio/drug/gia632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07431177-1372@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20280606
DTEND;VALUE=DATE:20280607
SUMMARY:GIA632: Phase 2 readout est. (NCT07431177)
DESCRIPTION:GIA632\, phase 2\, Vitiligo.\nStudy: A Phase IIb Dose-ranging S
 tudy to Assess the Efficacy and Safety of GIA632 in Participants With Non-
 segmental Vitiligo\nEstimated primary completion: 6 June 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/gia632#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT07431177
URL:https://assetmemo.bio/drug/gia632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07775924-1372@assetmemo.bio
DTSTAMP:20261121T005653Z
DTSTART;VALUE=DATE:20281122
DTEND;VALUE=DATE:20281123
SUMMARY:GIA632: Phase 2 readout est. (NCT07775924)
DESCRIPTION:GIA632\, phase 2.\nStudy: A Study to Assess the Efficacy and Sa
 fety of GIA632 Across a Range of Doses in Participants With Moderate to Se
 vere Cutaneous Lichen Planus\nEstimated primary completion: 22 November 20
 28. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\,
  and it can move.\nDrug page: https://assetmemo.bio/drug/gia632#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT07775924
URL:https://assetmemo.bio/drug/gia632#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
